KeyCorp Forecasts Strong Price Appreciation for Elanco Animal Health (NYSE:ELAN) Stock

Posted by Defense World Staff on Feb 27th, 2026

Elanco Animal Health (NYSE:ELAN – Get Free Report) had its target price increased by equities research analysts at KeyCorp from $27.00 to $29.00 in a report released on Wednesday, Marketbeat reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s price target points to a potential upside of 10.81% from the stock’s previous close.

A number of other analysts also recently issued reports on ELAN. JPMorgan Chase & Co. raised their target price on Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, February 19th. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $24.00 to $30.00 in a report on Thursday, January 22nd. Leerink Partners lifted their target price on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. Finally, Morgan Stanley raised their price target on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Read Our Latest Report on Elanco Animal Health

Elanco Animal Health Trading Down 2.5%

ELAN opened at $26.17 on Wednesday. The firm has a market capitalization of $13.01 billion, a price-to-earnings ratio of -54.52, a price-to-earnings-growth ratio of 3.98 and a beta of 1.87. The company’s 50 day simple moving average is $24.15 and its two-hundred day simple moving average is $21.69. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $27.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.23.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the business earned $0.14 earnings per share. The business’s revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Activity at Elanco Animal Health

In related news, insider Rajeev A. Modi acquired 4,500 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the acquisition, the insider owned 123,082 shares in the company, valued at $2,625,339.06. The trade was a 3.79% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average cost of $21.30 per share, with a total value of $213,000.00. Following the transaction, the director directly owned 131,773 shares in the company, valued at $2,806,764.90. This trade represents a 8.21% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by corporate insiders.

Institutional Trading of Elanco Animal Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELAN. NewEdge Advisors LLC boosted its position in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares during the period. SJS Investment Consulting Inc. raised its holdings in shares of Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares during the period. Root Financial Partners LLC lifted its stake in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new position in Elanco Animal Health during the 4th quarter valued at about $41,000. Finally, Huntington National Bank grew its position in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after acquiring an additional 1,087 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

More Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

Positive Sentiment: Q4 earnings beat and upbeat outlook: Elanco reported stronger-than-expected Q4 revenue and an EPS beat, gave Q1 and FY 2026 EPS guidance, and the stock hit a new 12‑month high on the reaction. This is the primary fundamental driver of the recent rally. Elanco Animal Health Inc (ELAN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst …
Positive Sentiment: Analyst bullishness: Multiple firms raised targets — KeyCorp boosted its PT to $29 (overweight) and Leerink raised its PT to $30 — reinforcing upside expectations and supporting investor sentiment. ‘Elanco Animal Health (ELAN) set up well for beats and raises’; PT Raised to $29 at KeyBanc Leerink Partners Boosts Elanco Animal Health (NYSE:ELAN) Price Target to $30.00
Positive Sentiment: Short interest fell materially in February (down ~20.7%), reducing a source of selling pressure and lowering the potential for short-driven downside. (Data summarized in filings/market reports.)
Positive Sentiment: High-profile media coverage: Jim Cramer highlighted Elanco’s “comeback story” and CEO Jeff Simmons appeared in an interview, increasing retail/institutional visibility and demand. Jim Cramer Highlights Elanco’s “Comeback Story” Elanco Animal Health CEO Jeff Simmons goes one-on-one with Jim Cramer
Neutral Sentiment: Investor presentation: Elanco presented at the BofA Securities Animal Health Summit (transcript available) — useful for modelers but less immediately market-moving than earnings and PT changes. Elanco Animal Health Incorporated (ELAN) Presents at BofA Securities Animal Health Summit Transcript
Neutral Sentiment: Strategic collaboration in Japan: Amlan International and Elanco are running calf‑health educational seminars in Japan — a positive commercial/branding initiative but unlikely to move near‑term results materially. Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health
Negative Sentiment: More conservative shop: Morgan Stanley raised its price target modestly to $24 but kept an “equal weight” rating — that PT sits below recent market price and signals at least one analyst sees limited near‑term upside. Morgan Stanley Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.